5 Big Pharma Stocks With the Best Drug Pipelines
Big pharma companies can't rest on their laurels. Continual research and development is critical to ensure long-term success. Some of that R&D pays off more than others, though.
Market research firm EvaluatePharma recently released its report looking at the state of the biopharmaceutical industry five years from now. One key area the firm researched was the potential value creation from pipeline products between now and 2022. Here's why Roche (NASDAQOTH: RHHBY), AstraZeneca (NYSE: AZN), AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ) ranked at the top.
Image source: Getty Images.
Source: Fool.com
Johnson & Johnson Stock
€145.78
0.230%
The stock is one of the favorites of our community with 41 Buy predictions and 1 Sell predictions.
With a target price of 196 € there is a positive potential of 34.45% for Johnson & Johnson compared to the current price of 145.78 €.
